BACKGROUND: The presence of positive soft tissue surgical margins (STSM) at radical cystectomy (RC) is rare. Although some patients with STSM experience disease recurrence rapidly, some have long-term local disease control. We sought to describe the oncologic outcomes, identify predictors, and assess the impact of location and multifocality in patients with positive STSMs at RC. METHODS: We retrospectively collected the data of 4,335 patients treated with RC and pelvic lymphadenectomy at 11 academic centers from 1981 to 2008. STSM was defined as the presence of tumor at inked areas of soft tissue on the RC specimen. Univariate and multivariate Cox regression models addressed recurrence-free survival and cancer-specific survival after surgery. RESULTS: STSM were identified in 231 patients (5%). Actuarial recurrence-free survival estimates at 2 and 5 years after RC were 26 ± 3 and 21 ± 3%, respectively. Actuarial cancer-specific survival estimates at 2 and 5 years after RC were 33 ± 3 and 25 ± 4%, respectively. Higher body mass index (p = 0.050), higher tumor stage (p = 0.017), presence of grade 3 disease (p = 0.046), lymphovascular invasion (p = 0.003), and lymph node involvement (p = 0.003) were all independently associated with disease recurrence. Furthermore, higher tumor stage (p = 0.015), lymphovascular invasion (p = 0.006), and lymph node involvement (p = 0.006) were independently associated with cancer specific mortality. Location and multifocality of STSM were not associated with outcomes. CONCLUSIONS: Although most patients with STSM at RC had poor outcomes, more than one-fifth had durable cancer control. Pathologic features associated with disease recurrence in the general RC population also stratify patients with STSM into differential risk groups.
BACKGROUND: The presence of positive soft tissue surgical margins (STSM) at radical cystectomy (RC) is rare. Although some patients with STSM experience disease recurrence rapidly, some have long-term local disease control. We sought to describe the oncologic outcomes, identify predictors, and assess the impact of location and multifocality in patients with positive STSMs at RC. METHODS: We retrospectively collected the data of 4,335 patients treated with RC and pelvic lymphadenectomy at 11 academic centers from 1981 to 2008. STSM was defined as the presence of tumor at inked areas of soft tissue on the RC specimen. Univariate and multivariate Cox regression models addressed recurrence-free survival and cancer-specific survival after surgery. RESULTS: STSM were identified in 231 patients (5%). Actuarial recurrence-free survival estimates at 2 and 5 years after RC were 26 ± 3 and 21 ± 3%, respectively. Actuarial cancer-specific survival estimates at 2 and 5 years after RC were 33 ± 3 and 25 ± 4%, respectively. Higher body mass index (p = 0.050), higher tumor stage (p = 0.017), presence of grade 3 disease (p = 0.046), lymphovascular invasion (p = 0.003), and lymph node involvement (p = 0.003) were all independently associated with disease recurrence. Furthermore, higher tumor stage (p = 0.015), lymphovascular invasion (p = 0.006), and lymph node involvement (p = 0.006) were independently associated with cancer specific mortality. Location and multifocality of STSM were not associated with outcomes. CONCLUSIONS: Although most patients with STSM at RC had poor outcomes, more than one-fifth had durable cancer control. Pathologic features associated with disease recurrence in the general RC population also stratify patients with STSM into differential risk groups.
Authors: Vladimir Novotny; Michael Froehner; Matthias May; Chris Protzel; Katrin Hergenröther; Michael Rink; Felix K Chun; Margit Fisch; Florian Roghmann; Rein-Jüri Palisaar; Joachim Noldus; Michael Gierth; Hans-Martin Fritsche; Maximilian Burger; Danijel Sikic; Bastian Keck; Bernd Wullich; Philipp Nuhn; Alexander Buchner; Christian G Stief; Stefan Vallo; Georg Bartsch; Axel Haferkamp; Patrick J Bastian; Oliver W Hakenberg; Stefan Propping; Atiqullah Aziz Journal: World J Urol Date: 2015-02-08 Impact factor: 4.226
Authors: Kamran Zargar-Shoshtari; Homayoun Zargar; Colin P Dinney; Cesar E Ercole; Pranav Sharma; Evan Kovac; Petros D Grivas; Andrew J Stephenson; Jay B Shah; Peter C Black; Philippe E Spiess Journal: World J Urol Date: 2015-08-19 Impact factor: 4.226
Authors: Marco Moschini; Stefania Zamboni; Francesco Soria; Romain Mathieu; Evanguelos Xylinas; Wei Shen Tan; John D Kelly; Giuseppe Simone; Anoop Meraney; Suprita Krishna; Badrinath Konety; Agostino Mattei; Philipp Baumeister; Livio Mordasini; Francesco Montorsi; Alberto Briganti; Andrea Gallina; Armando Stabile; Rafael Sanchez-Salas; Xavier Cathelineau; Michael Rink; Andrea Necchi; Pierre I Karakiewicz; Morgan Rouprêt; Anthony Koupparis; Wassim Kassouf; Douglas S Scherr; Guillaume Ploussard; Stephen A Boorjian; Yair Lotan; Prasanna Sooriakumaran; Shahrokh F Shariat Journal: J Clin Med Date: 2019-08-09 Impact factor: 4.241
Authors: Frederik König; Benjamin Pradere; Nico C Grossmann; Fahad Quhal; Pawel Rajwa; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Takafumi Yanagisawa; Hadi Mostafai; Reza Sari Motlagh; Abdulmajeed Aydh; Roland Dahlem; Shahrokh F Shariat; Michael Rink Journal: Transl Cancer Res Date: 2022-04 Impact factor: 1.241